Efficacy and Safety of Allogenic Stem Cell Product(CARTISTEM®) for Osteochondral Lesion of Talus

Phase 3 Completed 102 enrolled Hyundai Bioland Co., Ltd. Medipost Co Ltd. · collab

RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of adding CARTISTEM®(allogenic umbilical cord blood-derived stem cell product) on microfracture, a currently standard treatment for OLT, in patients with talar chondral or osteochondral defect.

Timeline

Start: 2020-03-03
Primary completion: 2022-06-13
Completion: 2022-06-13

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	CARTISTEM	Cell therapy	500 unknown	—

Indications

No indication recorded.